Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

Activist investor Starboard Value has amassed a stake in chip maker Qorvo that’s worth half a billion dollars, according to a ...

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

Wedmont Private Capital lessened its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 17.7% in the fourth ...

Brookstone Capital Management trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.9% in the fourth ...

A Washington jury ordered Bayer to pay $100 million to individuals sickened by toxic PCBs at a Seattle school, marking the latest courtroom challenge for the company. Meanwhile, Pfizer is reducing its ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

At $132 per share, J&J paid a 39% premium on Friday’s closing price of Intra-Cellular, a New York City based biotech that ...

Pfizer expects the acquisition of Seagen to contribute more than $10 billion in 2030 risk-adjusted revenues with potential significant growth beyond 2030.